Oklahoma 2023 Regular Session

Oklahoma House Bill HB2818

Introduced
2/6/23  
Refer
2/7/23  
Report Pass
3/2/23  
Engrossed
3/13/23  
Refer
3/30/23  
Report Pass
4/12/23  
Enrolled
4/20/23  

Caption

Sunset; Opioid Overdose Fatality Review Board; re-creating Board; modifying termination date.

Impact

Should this bill be enacted, it will have significant implications for state laws related to public health and the management of opioid crises. The renewal of the Opioid Overdose Fatality Review Board ensures that efforts are sustained in monitoring overdose trends, analyzing data, and formulating informed prevention strategies. It reinforces a structured method for reviewing overdose deaths that will assist in resource allocation and intervention planning at both state and community levels.

Summary

House Bill 2818 aims to renew the Opioid Overdose Fatality Review Board, extending its operational period until July 1, 2025. This Board is crucial in coordinating state and local efforts to address and prevent opioid overdose deaths. The legislation includes duties such as conducting case reviews of overdose fatalities, creating a comprehensive database on such deaths, and making recommendations to improve policies and practices in health and law enforcement agencies. It emphasizes a collaborative approach to combatting the opioid crisis based on data-driven insights.

Sentiment

The sentiment around HB 2818 is largely supportive, focusing on the necessity of a cohesive strategy to address the opioid epidemic. Legislators and health advocates view the bill as a vital tool that will enable the state to enhance its response to opioid-related fatalities, thereby filling gaps in public health policy. The direction of the discussions suggests a consensus that collective action through the review board is essential to mitigate the crisis having impacted many families and communities.

Contention

While general sentiment is supportive, there could be contention regarding the operational aspects and potential bureaucratic hurdles in the Board's functioning. Some may raise concerns about privacy issues associated with the collection of data and case reviews, especially regarding the confidentiality of individual medical records and how data is shared amongst public entities. Ensuring that the Board operates within the bounds of the law while maximizing its effectiveness to deliver results will be a point of focus in future discussions surrounding HB 2818.

Companion Bills

No companion bills found.

Similar Bills

No similar bills found.